144 related articles for article (PubMed ID: 29332874)
1. [Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity].
Tanaka T; Kozakai T; Kitajima T; Fuse K; Kobayashi H; Ushiki T; Shibazaki Y; Moriyama M; Takizawa J; Sone H; Fuse I; Masuko M
Rinsho Ketsueki; 2017; 58(12):2402-2405. PubMed ID: 29332874
[TBL] [Abstract][Full Text] [Related]
2. Lobectomy for lung cancer in a myelodysplastic syndrome patient with decreasing platelet aggregation: report of a case.
Koezuka S; Hata Y; Otsuka H; Makino T; Azuma Y; Azumi T; Anami Y; Natori K; Iyoda A
J Cardiothorac Surg; 2018 Jul; 13(1):89. PubMed ID: 30041670
[TBL] [Abstract][Full Text] [Related]
3. [Case of uremic platelet dysfunction].
Ohzeki M; Fukushima T; Arakawa S; Ozeki M; Kosaka Y; Kobayashi S; Namikoshi T; Haruna Y; Sasaki T; Kashihara N
Nihon Jinzo Gakkai Shi; 2005; 47(7):834-8. PubMed ID: 16296414
[TBL] [Abstract][Full Text] [Related]
4. Bernard-Soulier-like functional platelet defect in myelodysplastic syndrome and in acute myeloblastic leukemia associated with trilineage myelodysplasia.
Hiçsönmez G; Gümrük F; Cetin M; Ozbek N; Tuncer M; Gürsel T
Turk J Pediatr; 1995; 37(4):425-9. PubMed ID: 8560614
[TBL] [Abstract][Full Text] [Related]
5. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
[TBL] [Abstract][Full Text] [Related]
6. Platelet dysfunction in acute leukemias and myelodysplastic syndromes.
Vlădăreanu AM; Vasilache V; Bumbea H; Onisâi M
Rom J Intern Med; 2011; 49(1):93-6. PubMed ID: 22026258
[TBL] [Abstract][Full Text] [Related]
7. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.
Mo A; Wood E; Shortt J; Hu E; McQuilten Z
Eur J Haematol; 2023 Oct; 111(4):592-600. PubMed ID: 37452616
[TBL] [Abstract][Full Text] [Related]
8. Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Popov VM; Vladareanu AM; Bumbea H; Kovacs E; Savopol T; Iordache MM; Moisescu MG
Blood Coagul Fibrinolysis; 2015 Oct; 26(7):743-9. PubMed ID: 25811447
[TBL] [Abstract][Full Text] [Related]
9. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study.
Manoharan A; Brighton T; Gemmell R; Lopez K; Moran S; Kyle P
Int J Hematol; 2002 Oct; 76(3):272-8. PubMed ID: 12416739
[TBL] [Abstract][Full Text] [Related]
10. Acquired platelet function defects.
Bick RL
Hematol Oncol Clin North Am; 1992 Dec; 6(6):1203-28. PubMed ID: 1452509
[TBL] [Abstract][Full Text] [Related]
11. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding.
Fricke W; Alling D; Kimball J; Griffith P; Klein H
Transfusion; 1991 May; 31(4):345-8. PubMed ID: 1823527
[TBL] [Abstract][Full Text] [Related]
12. [Successful corticosteroid treatment of thrombocytopenia in a pregnant woman with myelodysplastic syndrome (refractory anemia)].
Murase K; Matsunaga T; Takimoto R; Takahira N; Fujimi A; Takeuchi N; Terui T; Niitsu Y
Rinsho Ketsueki; 2004 May; 45(5):383-6. PubMed ID: 15199747
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome.
Park SJ; Han CW; Lee JH; Eom HS; Lee SH; Jeong DC; Lim JH
Acta Haematol; 2003; 110(1):36-40. PubMed ID: 12975556
[TBL] [Abstract][Full Text] [Related]
15. Defective platelet aggregation in myelodysplastic syndromes.
Girtovitis FI; Ntaios G; Papadopoulos A; Ioannidis G; Makris PE
Acta Haematol; 2007; 118(2):117-22. PubMed ID: 17726306
[TBL] [Abstract][Full Text] [Related]
16. Platelet function and its clinical significance in the myelodysplastic syndromes.
Zeidman A; Sokolover N; Fradin Z; Cohen A; Redlich O; Mittelman M
Hematol J; 2004; 5(3):234-8. PubMed ID: 15167910
[TBL] [Abstract][Full Text] [Related]
17. A new platelet parameter, the mean platelet component, can demonstrate abnormal platelet function and structure in myelodysplasia.
Brummitt DR; Barker HF; Pujol-Moix N
Clin Lab Haematol; 2003 Feb; 25(1):59-62. PubMed ID: 12542444
[TBL] [Abstract][Full Text] [Related]
18. Acquired platelet dysfunction and overproduction of platelet cyclic AMP in two patients with myeloid malignancies.
Lecchi A; Femia EA; La Marca S; Onida F; Artoni A
Platelets; 2019; 30(8):1053-1056. PubMed ID: 31240986
[TBL] [Abstract][Full Text] [Related]
19. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome.
Yu QH; Shen YP; Ye BD; Zhou YH
Platelets; 2015; 26(2):195-6. PubMed ID: 23634876
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of thrombotic and hemorrhagic complications in myeloproliferative and myelodysplastic syndromes].
Vlădăreanu AM; Popov V; Bumbea H; Ciufu C; Vasilache V; Petre A; Onisâi M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):14-9. PubMed ID: 21688554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
